Catatonia: short-term response to lorazepam and dopaminergic metabolism

G. Northoff, J. Wenke, L. Demisch, J. Eckert, B. Gille, B. Pflug

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Therapeutic response to lorazepam and dopaminergic metabolism were investigated in 18 neuroleptically naive acute catatonic patients. They were diagnosed as catatonic according to criteria by Lohr and Rosebush and treated exclusively with lorazepam (2-4 mg) during the first 24 h. Dopaminergic metabolism (plasma HVA, plasma MHPG), anxiety (HAM-A) and parkinsonic/dyskinetic movements (SEPS, AIMS) were measured under standard conditions before initial treatment with lorazepam (day 0) and 24 h after initial treatment (day 1). On day 0 responders to lorazepam treatment (complete remission of catatonic syndrome after 24 h according to Rosebush and Lohr) showed significantly higher (P=0.004) plasma HVA (130.4±51.2 pmol/ml; means ± SD) than non-responders (no remission of catatonic syndrome after 24 h; 73.2±40.5 pmol/ml; means ± SD). On day 1 plasma HVA did not differ any more significantly between both groups Clinically, responders showed significantly higher HAM-A (P=0.025) and AIMS (P=0.022) scores as well as significantly lower SEPS (P=0.049) scores than non-responders on day 0. Hence catatonic short-term responders and non-responders to lorazepam can be distinguished with regard to plasma HVA, anxiety and dyskinetic/parkinsonic movements.

Original languageEnglish
Pages (from-to)182-186
Number of pages5
JournalPsychopharmacology
Volume122
Issue number2
DOIs
Publication statusPublished - Nov 1995

Fingerprint

Catatonia
Lorazepam
Methoxyhydroxyphenylglycol
Anxiety
Therapeutics

Keywords

  • Anxiety
  • Catatonic syndrome
  • Lorazepam
  • Movements
  • Plasma, HVA

ASJC Scopus subject areas

  • Pharmacology

Cite this

Northoff, G., Wenke, J., Demisch, L., Eckert, J., Gille, B., & Pflug, B. (1995). Catatonia: short-term response to lorazepam and dopaminergic metabolism. Psychopharmacology, 122(2), 182-186. https://doi.org/10.1007/BF02246093

Catatonia : short-term response to lorazepam and dopaminergic metabolism. / Northoff, G.; Wenke, J.; Demisch, L.; Eckert, J.; Gille, B.; Pflug, B.

In: Psychopharmacology, Vol. 122, No. 2, 11.1995, p. 182-186.

Research output: Contribution to journalArticle

Northoff, G, Wenke, J, Demisch, L, Eckert, J, Gille, B & Pflug, B 1995, 'Catatonia: short-term response to lorazepam and dopaminergic metabolism', Psychopharmacology, vol. 122, no. 2, pp. 182-186. https://doi.org/10.1007/BF02246093
Northoff, G. ; Wenke, J. ; Demisch, L. ; Eckert, J. ; Gille, B. ; Pflug, B. / Catatonia : short-term response to lorazepam and dopaminergic metabolism. In: Psychopharmacology. 1995 ; Vol. 122, No. 2. pp. 182-186.
@article{5a5dcce29f0e42bbba9bdbdf3b2f4155,
title = "Catatonia: short-term response to lorazepam and dopaminergic metabolism",
abstract = "Therapeutic response to lorazepam and dopaminergic metabolism were investigated in 18 neuroleptically naive acute catatonic patients. They were diagnosed as catatonic according to criteria by Lohr and Rosebush and treated exclusively with lorazepam (2-4 mg) during the first 24 h. Dopaminergic metabolism (plasma HVA, plasma MHPG), anxiety (HAM-A) and parkinsonic/dyskinetic movements (SEPS, AIMS) were measured under standard conditions before initial treatment with lorazepam (day 0) and 24 h after initial treatment (day 1). On day 0 responders to lorazepam treatment (complete remission of catatonic syndrome after 24 h according to Rosebush and Lohr) showed significantly higher (P=0.004) plasma HVA (130.4±51.2 pmol/ml; means ± SD) than non-responders (no remission of catatonic syndrome after 24 h; 73.2±40.5 pmol/ml; means ± SD). On day 1 plasma HVA did not differ any more significantly between both groups Clinically, responders showed significantly higher HAM-A (P=0.025) and AIMS (P=0.022) scores as well as significantly lower SEPS (P=0.049) scores than non-responders on day 0. Hence catatonic short-term responders and non-responders to lorazepam can be distinguished with regard to plasma HVA, anxiety and dyskinetic/parkinsonic movements.",
keywords = "Anxiety, Catatonic syndrome, Lorazepam, Movements, Plasma, HVA",
author = "G. Northoff and J. Wenke and L. Demisch and J. Eckert and B. Gille and B. Pflug",
year = "1995",
month = "11",
doi = "10.1007/BF02246093",
language = "English",
volume = "122",
pages = "182--186",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Catatonia

T2 - short-term response to lorazepam and dopaminergic metabolism

AU - Northoff, G.

AU - Wenke, J.

AU - Demisch, L.

AU - Eckert, J.

AU - Gille, B.

AU - Pflug, B.

PY - 1995/11

Y1 - 1995/11

N2 - Therapeutic response to lorazepam and dopaminergic metabolism were investigated in 18 neuroleptically naive acute catatonic patients. They were diagnosed as catatonic according to criteria by Lohr and Rosebush and treated exclusively with lorazepam (2-4 mg) during the first 24 h. Dopaminergic metabolism (plasma HVA, plasma MHPG), anxiety (HAM-A) and parkinsonic/dyskinetic movements (SEPS, AIMS) were measured under standard conditions before initial treatment with lorazepam (day 0) and 24 h after initial treatment (day 1). On day 0 responders to lorazepam treatment (complete remission of catatonic syndrome after 24 h according to Rosebush and Lohr) showed significantly higher (P=0.004) plasma HVA (130.4±51.2 pmol/ml; means ± SD) than non-responders (no remission of catatonic syndrome after 24 h; 73.2±40.5 pmol/ml; means ± SD). On day 1 plasma HVA did not differ any more significantly between both groups Clinically, responders showed significantly higher HAM-A (P=0.025) and AIMS (P=0.022) scores as well as significantly lower SEPS (P=0.049) scores than non-responders on day 0. Hence catatonic short-term responders and non-responders to lorazepam can be distinguished with regard to plasma HVA, anxiety and dyskinetic/parkinsonic movements.

AB - Therapeutic response to lorazepam and dopaminergic metabolism were investigated in 18 neuroleptically naive acute catatonic patients. They were diagnosed as catatonic according to criteria by Lohr and Rosebush and treated exclusively with lorazepam (2-4 mg) during the first 24 h. Dopaminergic metabolism (plasma HVA, plasma MHPG), anxiety (HAM-A) and parkinsonic/dyskinetic movements (SEPS, AIMS) were measured under standard conditions before initial treatment with lorazepam (day 0) and 24 h after initial treatment (day 1). On day 0 responders to lorazepam treatment (complete remission of catatonic syndrome after 24 h according to Rosebush and Lohr) showed significantly higher (P=0.004) plasma HVA (130.4±51.2 pmol/ml; means ± SD) than non-responders (no remission of catatonic syndrome after 24 h; 73.2±40.5 pmol/ml; means ± SD). On day 1 plasma HVA did not differ any more significantly between both groups Clinically, responders showed significantly higher HAM-A (P=0.025) and AIMS (P=0.022) scores as well as significantly lower SEPS (P=0.049) scores than non-responders on day 0. Hence catatonic short-term responders and non-responders to lorazepam can be distinguished with regard to plasma HVA, anxiety and dyskinetic/parkinsonic movements.

KW - Anxiety

KW - Catatonic syndrome

KW - Lorazepam

KW - Movements

KW - Plasma, HVA

UR - http://www.scopus.com/inward/record.url?scp=0029619327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029619327&partnerID=8YFLogxK

U2 - 10.1007/BF02246093

DO - 10.1007/BF02246093

M3 - Article

C2 - 8848534

AN - SCOPUS:0029619327

VL - 122

SP - 182

EP - 186

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -